Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

Merck & Co’s attempts to move its checkpoint inhibitor Keytruda into prostate cancer have been blocked once again, continuing a run of disappointing studies with immunotherapies in the disease.

Keytruda (pembrolizumab) contributed almost $2.3 billion out of Merck’s total sales of $10.8 billion in the quarter, a 55% rise that was driven by use in first-line non-small cell lung cancer ...

Merck is injecting $1 billion into a new facility in Wilmington, Delaware to amp up U.S. drug production, especially for its ...

Amazon was struggling before mixed second-quarter results, but it has several attractive growth opportunities. Mounting ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...